The FDA has set a PDUFA target action date of October 23, 2025, for the low-dose atropine formulation.

The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for SYD-101 (atropine sulfate) to slow the progression of ...

In December, the U.S.-based National Academy of Sciences published a report classifying myopia, for the first time, as a ...

The FDA accepted a new drug application for SYD-101 to slow the progression of pediatric myopia and assigned a Prescription ...

Sydnexis, Inc. ( a pre-commercial stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration ...

“We are the custodians of people’s eye health over their lifetimes,” she said. Through her role as an ophthalmologist, Dahlmann-Noor has observed the effect that being myopic can have on a young ...

Paediatric ophthalmologist, Dr Katie Williams, discusses her research exploring factors associated with myopia ...

Every morning – shortly after checking my phone and shortly before brushing my teeth – I pull down my lower eyelids in turn ...

Brianna Rhue, OD, FAAO, discusses the pitfalls of myopia treatment and accessibility of that treatment. There are still some ...

Nam Quoc Bui, MD, discusses survival, symptom control, and ovarian toxicity in the DeFi trial of nirogacestat in patients ...